Case ReportRenal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma
References (10)
- et al.
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Biochem Biophys Res Commun
(2005) - et al.
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology
Kidney Int
(2004) - et al.
A new model of renal microvascular endothelial injury
Kidney Int
(1997) - et al.
Clinical cancer advances 2005: major research advances in cancer treatment, prevention and screening: a report from the American society of clinical oncology
J Clin Oncol
(2006) - et al.
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
J Clin Oncol
(2006)
Cited by (127)
Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents
2021, Advances in Chronic Kidney DiseaseCitation Excerpt :As the kidney-associated clinical abnormalities cannot always predict underlying kidney lesions, kidney biopsy may help identify VEGF inhibitor–associated glomerular TMA, even in the absence of typical clinical manifestations of TMA. The influence of prior biopsy-proven TMA cases or concomitant chemotherapies, such as gemcitabine, cisplatin, and interferon-α, should be considered as having a possible role in the development of TMA in the previously reported patients.5,96,97,103 In addition to glomerular TMA, various other glomerular diseases, such as cryoglobulinemic glomerulonephritis, collapsing FSGS, immune-complex-mediated proliferative glomerulonephritis, and crescentic glomerulonephritis, as well as interstitial nephritis, have been reported with VEGF inhibitors.3,37,104,105
Anticancer Drugs and the Kidney
2019, Critical Care Nephrology: Third EditionThrombotic microangiopathy and cancer
2017, Nephrologie et TherapeutiqueCollapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney
2016, Kidney InternationalThrombotic Microangiopathy, Cancer, and Cancer Drugs
2015, American Journal of Kidney DiseasesCitation Excerpt :Antitumor effects of VEGF inhibition have been ascribed to reduction in tumor microvessel density and tumor blood flow through deprivation of tumor vascular supply and inhibition of endothelial proliferation. All targeted cancer agents (Table 2) have been linked to the development of a syndrome characterized by new-onset hypertension (or exacerbation of preexisting hypertension), proteinuria, severe hypertension, and/or AKI or chronic kidney injury (with or without proteinuria), and histopathologic evidence of kidney TMA.7,87-107 In our largest series of patients with biopsy-proven kidney damage during anti-VEGF therapy, intraglomerular TMA occurred preferentially with VEGF-ligand exposure, whereas podocytopathies such as minimal change nephropathy/collapsing focal glomerulosclerosis were more often associated with tyrosine kinase inhibitors, although there was some overlap of kidney lesions.7